MCID: THY123
MIFTS: 48

Thyroid Gland Follicular Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Follicular Carcinoma

MalaCards integrated aliases for Thyroid Gland Follicular Carcinoma:

Name: Thyroid Gland Follicular Carcinoma 12
Follicular Thyroid Carcinoma 12 15
Follicular Adenocarcinoma, Well Differentiated 12
Adenocarcinoma, Follicular 43
Follicular Adenocarcinoma 12
Thyroid Adenocarcinoma 12
Follicular Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3962
MeSH 43 D018263
NCIt 49 C8054
SNOMED-CT 67 28173006 5257006
UMLS 71 C0206682

Summaries for Thyroid Gland Follicular Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that has material basis in follicular cells.

MalaCards based summary : Thyroid Gland Follicular Carcinoma, also known as follicular thyroid carcinoma, is related to graves disease 1 and hyperthyroidism. An important gene associated with Thyroid Gland Follicular Carcinoma is RET (Ret Proto-Oncogene), and among its related pathways/superpathways is Thyroxine (Thyroid Hormone) Production. The drugs Anti-Infective Agents and Nutrients have been mentioned in the context of this disorder. Affiliated tissues include thyroid, pituitary and bone, and related phenotypes are nervous system and no phenotypic analysis

Related Diseases for Thyroid Gland Follicular Carcinoma

Diseases related to Thyroid Gland Follicular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 377)
# Related Disease Score Top Affiliating Genes
1 graves disease 1 31.1 TSHR TG CALCA
2 hyperthyroidism 31.1 TSHR TG SST CALCA
3 fetal adenoma 31.0 TG CALCA
4 benign mesothelioma 30.9 PAX8 CEACAM5
5 rare tumor 30.9 SST RET
6 renal cell carcinoma, nonpapillary 30.8 RET PAX8 NKX2-1 MIR9-1 MIR183 MIR144
7 follicular adenoma 30.8 TSHR TG RET PAX8 NTRK1 NKX2-1
8 endemic goiter 30.8 TSHR TG CHST14 CALCA
9 congenital hypothyroidism 30.7 TSHR TG PAX8 NKX2-1
10 struma ovarii 30.7 TSHR TG RET NKX2-1 NCOA4
11 nontoxic goiter 30.7 TSHR TG CALCA
12 parathyroid adenoma 30.6 RET LGALS3 CHGA CALCA
13 nodular goiter 30.6 TSHR TG RET LGALS3 CALCA
14 teratoma 30.6 SST NKX2-1 CHGA CEACAM5
15 thyroid gland anaplastic carcinoma 30.6 TG RET PAX8 NKX2-1
16 thyroid tumor 30.6 TG RET LGALS3
17 thyroid cancer, nonmedullary, 2 30.6 TSHR TG PAX8 LGALS3 CALCA
18 nonencapsulated sclerosing carcinoma 30.6 TG RET CALCA
19 colloid adenoma 30.6 TG LGALS3
20 thyroiditis 30.5 TSHR TG RET NKX2-1 NCOA4 CALCA
21 papillary thyroid microcarcinoma 30.5 TSHR TG NKX2-1 CALCA
22 differentiated thyroid carcinoma 30.5 TSHR TG RET PAX8 NTRK1 NKX2-1
23 benign teratoma 30.4 TG NKX2-1 CEACAM5
24 primary hyperparathyroidism 30.4 RET CHGA CALCA
25 papillary carcinoma 30.4 TSHR TG RET PAX8 NTRK1 NKX2-1
26 hyperparathyroidism 30.4 RET CHGA CALCA
27 malignant struma ovarii 30.3 TG RET NKX2-1 NCOA4 LGALS3
28 olfactory neuroblastoma 30.3 SSTR2 NTRK1 NKX2-1 CHGA
29 hypothyroidism, congenital, nongoitrous, 2 30.3 TSHR TG PAX8 NKX2-1 LGALS3
30 hypothyroidism 30.3 TSHR TG SST RET PAX8 NKX2-1
31 cholangitis 30.2 SST MIR222 CEACAM5
32 multinodular goiter 30.2 TSHR TG PAX8 NKX2-1 MIR222 CALCA
33 hashimoto thyroiditis 30.2 TSHR TG RET NCOA4 LGALS3 CALCA
34 endocrine gland cancer 30.1 SST RET MIR9-1 MIR222 MIR183 MIR144
35 ovarian germ cell teratoma 30.1 TG RET NKX2-1 NCOA4 LGALS3
36 thyroid gland papillary carcinoma 30.1 TPCN1 TG RET PAX8 NKX2-1 NCOA4
37 thyroid carcinoma 30.0 TSHR TG RET NTRK1 NKX2-1 NCOA4
38 adenoma 29.9 TSHR SSTR2 SST RET LGALS3 CHGA
39 thyroid carcinoma, familial medullary 29.8 TG SSTR2 SST RET NTRK1 NKX2-1
40 gastric adenocarcinoma 29.8 SSTR2 SST LGALS3 CHGA CEACAM5
41 goiter 29.8 TSHR TG SST RET PAX8 NKX2-1
42 thyroid gland medullary carcinoma 29.2 TPCN1 TG SSTR2 SST RET PAX8
43 thyroid gland disease 28.9 TSHR TPCN1 TG SST RET PAX8
44 thyroid gland cancer 28.4 TSHR TPCN1 TG SSTR2 SST RET
45 familial papillary or follicular thyroid carcinoma 12.6
46 trabecular follicular adenocarcinoma 12.4
47 papillary follicular thyroid adenocarcinoma 12.3
48 thyroid carcinoma, hurthle cell 11.7
49 thyroid gland hurthle cell carcinoma 11.5
50 thyroid gland mucoepidermoid carcinoma 10.7 TG CALCA

Graphical network of the top 20 diseases related to Thyroid Gland Follicular Carcinoma:



Diseases related to Thyroid Gland Follicular Carcinoma

Symptoms & Phenotypes for Thyroid Gland Follicular Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Follicular Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.7 CHGA CHST14 LGALS3 NKX2-1 NTRK1 PAX8
2 no phenotypic analysis MP:0003012 9.17 CHGA NKX2-1 NTRK1 PAX8 RET SST

Drugs & Therapeutics for Thyroid Gland Follicular Carcinoma

Drugs for Thyroid Gland Follicular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Infective Agents Phase 2, Phase 3
2 Nutrients Phase 2, Phase 3
3 Trace Elements Phase 2, Phase 3
4 Micronutrients Phase 2, Phase 3
5 Anti-Infective Agents, Local Phase 2, Phase 3
6
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
7
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
8
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
9
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
10
Decitabine Approved, Investigational Phase 2 2353-33-5 451668
11
Durvalumab Approved, Investigational Phase 2 1428935-60-7
12
nivolumab Approved Phase 2 946414-94-4
13
Ipilimumab Approved Phase 2 477202-00-9
14
Pembrolizumab Approved Phase 2 1374853-91-4
15
Iodine Approved, Investigational Phase 2 7553-56-2 807
16
Lenvatinib Approved, Investigational Phase 2 417716-92-8
17
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
18
Lenalidomide Approved Phase 2 191732-72-6 216326
19
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
20
Trametinib Approved Phase 2 871700-17-3 11707110
21
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
22
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
23
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
24
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
25
Tremelimumab Investigational Phase 2 745013-59-6
26
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
27
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
28
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
29
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
30 Deoxyglucose Phase 2
31 Histone Deacetylase Inhibitors Phase 2
32 Antibiotics, Antitubercular Phase 2
33 Anti-Bacterial Agents Phase 2
34 Endothelial Growth Factors Phase 2
35 Fluorides Phase 2
36 Mitogens Phase 2
37 Antibodies, Monoclonal Phase 2
38 Antineoplastic Agents, Immunological Phase 2
39 cadexomer iodine Phase 2
40 Antibodies Phase 1, Phase 2
41 Immunologic Factors Phase 2
42 Immunoglobulins Phase 1, Phase 2
43 Angiogenesis Inhibitors Phase 2
44 topoisomerase I inhibitors Phase 1, Phase 2
45 Immunoconjugates Phase 1, Phase 2
46 Topoisomerase Inhibitors Phase 1, Phase 2
47 Hormones Phase 1, Phase 2
48 Katacalcin Phase 2
49 calcitonin Phase 2
50 Fluorodeoxyglucose F18 Phase 2

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
2 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
3 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
4 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
5 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
6 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
7 A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma Completed NCT00098813 Phase 2 romidepsin
8 Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine Completed NCT00085293 Phase 2 Decitabine
9 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2 SU011248, Sutent
10 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
11 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
12 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
13 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
14 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib;Cabozantinib S-malate
15 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Recruiting NCT02393690 Phase 2 Selumetinib
16 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Recruiting NCT02973997 Phase 2 Lenvatinib
17 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Recruiting NCT02152995 Phase 2 Trametinib
18 A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy Active, not recruiting NCT00537095 Phase 2 Vandetanib
19 Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas Active, not recruiting NCT00287287 Phase 2 Lenalidomide
20 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers Active, not recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
21 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
22 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma Active, not recruiting NCT01723202 Phase 2 dabrafenib;trametinib
23 Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer Active, not recruiting NCT03630120 Phase 2 Lenvatinib;Sorafenib;Cabozantinib;Vandetanib
24 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
25 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
26 A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
27 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
28 A Phase I Clinical Trial of Pazopanib in Combination With Escalating Doses of Radioactive 131I in Patients With Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake Completed NCT01413113 Phase 1 pazopanib hydrochloride
29 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
30 Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. Unknown status NCT01075269
31 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
32 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
33 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
34 Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone Completed NCT01441154
35 Studies on Thyroid Nodules and Thyroid Cancer Recruiting NCT00001160
36 Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions Recruiting NCT00001452
37 Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients Active, not recruiting NCT02862470
38 Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples Enrolling by invitation NCT02239575
39 Role of of F-18-fluoro-deoxy-glucose (FDG) PET/CT in Thyroid Cancer Patients With Negative I-131whole Body Scan and Elevated Thyroglobulin Level or Positive Anti Thyroglobulin Antibodies Not yet recruiting NCT04128631
40 Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer Compared With Usual Initial Management: Multicenter Randomized Prospective Study Not yet recruiting NCT03639662

Search NIH Clinical Center for Thyroid Gland Follicular Carcinoma

Cochrane evidence based reviews: adenocarcinoma, follicular

Genetic Tests for Thyroid Gland Follicular Carcinoma

Anatomical Context for Thyroid Gland Follicular Carcinoma

MalaCards organs/tissues related to Thyroid Gland Follicular Carcinoma:

40
Thyroid, Pituitary, Bone, Lung, Lymph Node, Kidney, Thymus

Publications for Thyroid Gland Follicular Carcinoma

Articles related to Thyroid Gland Follicular Carcinoma:

(show top 50) (show all 1214)
# Title Authors PMID Year
1
Ultrasound-guided Fine Needle Aspiration or Core Needle Biopsy for diagnosing follicular thyroid carcinoma? 61
32012326 2020
2
Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation. 61
31621921 2020
3
The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement. 61
31892961 2020
4
UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE. 61
31968199 2020
5
Can ultrasound systems for risk stratification of thyroid nodules identify follicular carcinoma? 61
31899594 2020
6
Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer. 61
31797753 2020
7
FDG PET/CT of Cervical Gout With Spinal Cord Compression. 61
31652157 2020
8
Macrofollicular Variant of Follicular Thyroid Carcinoma: A Rare Underappreciated Pitfall in the Diagnosis of Thyroid Carcinoma. 61
31701808 2020
9
Ultrasonographic features for differentiating follicular thyroid carcinoma and follicular adenoma. 61
31182260 2020
10
Staged surgical management of follicular thyroid carcinoma with extensive thrombus reaching up to right atrium - A case report. 61
31805428 2020
11
Hyperfunctioning thyroid carcinoma: A systematic review. 61
31798874 2019
12
Expression of long non-coding RNA H19 predicts distant metastasis in minimally invasive follicular thyroid carcinoma. 61
31791180 2019
13
[Individualization of the surgical procedure in response to overdiagnosis and overtreatment in differentiated thyroid carcinomas]. 61
31705233 2019
14
Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literature. 61
31679038 2019
15
A computer-aided diagnosing system in the evaluation of thyroid nodules-experience in a specialized thyroid center. 61
31810469 2019
16
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. 61
31637953 2019
17
Malignant struma ovarii presenting with follicular carcinoma: A case report with molecular analysis. 61
31538107 2019
18
Chest wall lymph node metastasis from follicular thyroid carcinoma: a rare case report. 61
31747942 2019
19
IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma. 61
31290966 2019
20
Signet ring cell variant of follicular thyroid carcinoma: Report of two cases with focus on morphological, expressional and genetic characteristics. 61
31699114 2019
21
Distant metastasis of follicular thyroid carcinoma to the mandible: a rare case report. 61
31728337 2019
22
Follicular Thyroid Carcinoma Presenting as a Large Rib Metastasis. 61
31569109 2019
23
Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. 61
31189769 2019
24
DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions. 61
31328658 2019
25
Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. 61
31397224 2019
26
Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule. 61
31211509 2019
27
Using deep convolutional neural networks for multi-classification of thyroid tumor by histopathology: a large-scale pilot study. 61
31700904 2019
28
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up. 61
31154561 2019
29
Correction: LncRNA HCP5A promotes follicular thyroid carcinoma progression via miRNAs sponge. 61
31481658 2019
30
Two distinct E3 ligases, SCFFBXL19 and HECW1, degrade thyroid transcription factor 1 in normal thyroid epithelial and follicular thyroid carcinoma cells, respectively. 61
31238008 2019
31
Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer. 61
31762750 2019
32
Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease. 61
31561592 2019
33
An unsuspicious thyroid nodule with fatal outcome. 61
31140157 2019
34
Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer. 61
31102936 2019
35
[The analysis of genetic and clinicopathologic characteristics in patients with follicular thyroid neoplasm]. 61
31434450 2019
36
The surgical dilemma of primary surgery for follicular thyroid neoplasms. 61
31434622 2019
37
Development and validation of a preoperative prediction model for follicular thyroid carcinoma. 61
31050007 2019
38
Prediction of follicular thyroid carcinoma associated with distant metastasis in the preoperative and postoperative model. 61
30891875 2019
39
Intraorbital, Infratemporal And Intracranial Extensions As The First Presentation Of Follicular Thyroid Carcinoma. 61
31535529 2019
40
Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell. 61
30747408 2019
41
Expression and clinicopathological role of miR146a in thyroid follicular carcinoma. 61
30701447 2019
42
Fine-needle aspiration cytology of metastatic spindle cell follicular thyroid carcinoma: A case report. 61
30794342 2019
43
Spectroscopic identification of benign (follicular adenoma) and cancerous lesions (follicular thyroid carcinoma) in thyroid tissues. 61
30954022 2019
44
Follicular Thyroid Carcinoma Presenting as a Manubrium Mass. 61
30973599 2019
45
Differences in Mutational Profile between Follicular Thyroid Carcinoma and Follicular Thyroid Adenoma Identified Using Next Generation Sequencing. 61
31248021 2019
46
Modified Transverse-Vertical Gross Examination: a Better Method for the Detection of Definite Capsular Invasion in Encapsulated Follicular-Patterned Thyroid Neoplasms. 61
30661168 2019
47
An Evaluation of CD61 Immunohistochemistry in Identification of Vascular Invasion in Follicular Thyroid Neoplasms. 61
31218593 2019
48
Mutation profiles of follicular thyroid tumors by targeted sequencing. 61
31077238 2019
49
A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert! 61
31131695 2019
50
Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. 61
30913992 2019

Variations for Thyroid Gland Follicular Carcinoma

Cosmic variations for Thyroid Gland Follicular Carcinoma:

9 (show top 50) (show all 660)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88291097 VHL thyroid,NS,carcinoma,follicular carcinoma c.232A>T p.N78Y 3:10142079-10142079 15
2 COSM131097634 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1859C>A p.T620N 14:81143917-81143917 15
3 COSM131092533 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 15
4 COSM131082578 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1867G>T p.A623S 14:81143925-81143925 15
5 COSM131082731 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 15
6 COSM131082360 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1358T>C p.M453T 14:81143416-81143416 15
7 COSM131085590 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 15
8 COSM131083920 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 15
9 COSM131084415 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 15
10 COSM85727602 TSC1 thyroid,NS,carcinoma,follicular carcinoma c.257G>T p.R86L 9:132925693-132925693 15
11 COSM94332969 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.776C>G p.A259G 7:98899743-98899743 15
12 COSM94306247 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.8716C>T p.R2906C 7:98981871-98981871 15
13 COSM94333970 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9314T>C p.I3105T 7:98984957-98984957 15
14 COSM94327035 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.4574C>T p.P1525L 7:98948267-98948267 15
15 COSM94307468 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.10775C>A p.S3592Y 7:99008440-99008440 15
16 COSM94311641 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9896G>A p.R3299H 7:98993628-98993628 15
17 COSM99622204 TP53BP1 thyroid,NS,carcinoma,follicular carcinoma c.3754C>A p.R1252S 15:43428090-43428090 15
18 COSM87898709 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 17:7674221-7674221 15
19 COSM88057483 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 17:7673745-7673745 15
20 COSM87907024 TP53 thyroid,NS,carcinoma,follicular carcinoma c.799C>T p.R267W 17:7673821-7673821 15
21 COSM87897832 TP53 thyroid,NS,carcinoma,follicular carcinoma c.725G>A p.C242Y 17:7674238-7674238 15
22 COSM87902369 TP53 thyroid,NS,carcinoma,follicular carcinoma c.1009C>T p.R337C 17:7670700-7670700 15
23 COSM87898881 TP53 thyroid,NS,carcinoma,follicular carcinoma c.578A>G p.H193R 17:7674953-7674953 15
24 COSM87898714 TP53 thyroid,NS,carcinoma,follicular carcinoma c.844C>T p.R282W 17:7673776-7673776 15
25 COSM87897745 TP53 thyroid,NS,carcinoma,follicular carcinoma c.524G>A p.R175H 17:7675088-7675088 15
26 COSM95652847 TNKS2 thyroid,NS,carcinoma,follicular carcinoma c.3037A>G p.R1013G 10:91857473-91857473 15
27 COSM90566787 TNKS thyroid,NS,carcinoma,follicular carcinoma c.1969G>C p.A657P 8:9726688-9726688 15
28 COSM107083861 TAF1 thyroid,NS,carcinoma,follicular carcinoma c.650A>T p.E217V 23:71377067-71377067 15
29 COSM90697568 STK11 thyroid,NS,carcinoma,follicular carcinoma c.662C>T p.P221L 19:1220645-1220645 15
30 COSM86759087 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.1100T>G p.F367C 23:124051203-124051203 15
31 COSM86759512 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.456C>G p.F152L 23:124042639-124042639 15
32 COSM151065421 SPTA1 thyroid,NS,carcinoma,follicular carcinoma c.2944G>T p.V982F 1:158654703-158654703 15
33 COSM99817024 SPEN thyroid,NS,carcinoma,follicular carcinoma c.971C>G p.S324* 1:15909410-15909410 15
34 COSM99809287 SPEN thyroid,NS,carcinoma,follicular carcinoma c.3793C>T p.R1265* 1:15930033-15930033 15
35 COSM86768394 SNCAIP thyroid,NS,carcinoma,follicular carcinoma c.601C>A p.L201M 5:122423197-122423197 15
36 COSM91381467 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 18:51058224-51058224 15
37 COSM91385702 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.1060G>C p.V354L 18:51065527-51065527 15
38 COSM92479962 SH2B3 thyroid,NS,carcinoma,follicular carcinoma c.640G>A p.G214R 12:111418785-111418785 15
39 COSM89623394 SF3B1 thyroid,NS,carcinoma,follicular carcinoma c.635C>T p.P212L 2:197416772-197416772 15
40 COSM103027987 SETD2 thyroid,NS,carcinoma,follicular carcinoma c.5068G>A p.G1690R 3:47098029-47098029 15
41 COSM93852061 ROS1 thyroid,NS,carcinoma,follicular carcinoma c.578T>C p.V193A 6:117397116-117397116 15
42 COSM140186576 RNF43 thyroid,NS,carcinoma,follicular carcinoma c.1082C>T p.P361L 17:58358694-58358694 15
43 COSM92347951 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 10:43120124-43120124 15
44 COSM92940024 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2461T>G p.W821G 23:47185541-47185541 15
45 COSM92935660 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.1888+1G>A p.? 23:47181867-47181867 15
46 COSM92935485 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2464C>T p.Q822* 23:47185544-47185544 15
47 COSM86627088 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 13:48459766-48459766 15
48 COSM86624126 RB1 thyroid,NS,carcinoma,follicular carcinoma c.751C>T p.R251* 13:48362847-48362847 15
49 COSM86626205 RB1 thyroid,NS,carcinoma,follicular carcinoma c.1363C>T p.R455* 13:48379624-48379624 15
50 COSM86625019 RB1 thyroid,NS,carcinoma,follicular carcinoma c.1510C>T p.Q504* 13:48381258-48381258 15

Expression for Thyroid Gland Follicular Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Follicular Carcinoma.

Pathways for Thyroid Gland Follicular Carcinoma

Pathways related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.4 TSHR TG

GO Terms for Thyroid Gland Follicular Carcinoma

Biological processes related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.55 MIR9-1 MIR222 MIR187 MIR183 MIR144
2 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.26 NTRK1 CALCA
3 thyroid gland development GO:0030878 9.13 TG PAX8 NKX2-1
4 thyroid-stimulating hormone signaling pathway GO:0038194 8.62 TSHR PAX8

Molecular functions related to Thyroid Gland Follicular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.35 MIR9-1 MIR222 MIR187 MIR183 MIR144
2 hormone activity GO:0005179 9.33 TG SST CALCA
3 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8

Sources for Thyroid Gland Follicular Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....